HEPA · Hepion Pharmaceuticals, Inc. - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | $0 | - |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - |
| R&D | $70.0K | - | - | $423.3K | $22.2K | - | $2.76M | $7.14M | $2.54M | - |
| SG&A | $728.5K | - | $527.9K | $919.5K | $1.26M | - | $1.70M | $1.37M | $2.64M | - |
| Total Operating Expenses | $798.5K | - | $527.9K | $1.75M | $1.28M | - | $4.46M | $8.50M | $5.18M | - |
| D&A | - | - | - | - | - | - | $0 | $0 | $30.8K | - |
| Operating Income | ($798.5K) | - | ($527.9K) | ($1.75M) | ($1.28M) | - | ($4.46M) | ($8.50M) | ($5.18M) | - |
| Interest Expense | - | - | - | - | - | - | - | - | $4.3K | - |
| Income Tax | - | - | - | - | - | - | - | - | ($2.97M) | - |
| Net Income | ($810.8K) | - | ($472.5K) | ($1.04M) | ($6.11M) | - | ($4.87M) | ($3.93M) | ($2.85M) | - |
| EPS - Basic | ($0.07) | - | ($0.04) | ($0.09) | ($2.15) | - | ($36.00) | ($34.00) | ($28.00) | - |
| EPS - Diluted | ($0.07) | - | ($0.04) | ($0.09) | ($2.15) | - | ($36.00) | ($34.00) | ($28.00) | - |
Balance Sheet
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $2.60M | $1.83M | $2.32M | $2.92M | $4.59M | $406.4K | $1.50M | $2.12M | $13.11M | $14.79M |
| Accounts Receivable | - | - | - | - | - | - | - | - | - | - |
| Inventory | - | - | - | - | - | - | - | - | - | - |
| Accounts Payable | $138.4K | $167.8K | $77.2K | $172.7K | $243.3K | $220.2K | $186.3K | $446.5K | $1.50M | $2.35M |
| Current Assets | $2.71M | $3.07M | $3.74M | $4.51M | $6.32M | $1.61M | $3.53M | $5.48M | $15.43M | $17.49M |
| Total Assets | $2.71M | $3.07M | $3.74M | $4.51M | $6.32M | $1.61M | $3.72M | $6.01M | $15.99M | $18.09M |
| Current Liabilities | $735.6K | $299.4K | $347.4K | $592.9K | $935.9K | $3.14M | $2.72M | $975.6K | $2.57M | $5.29M |
| Long-term Debt | - | - | - | - | - | - | - | - | - | - |
| Total Liabilities | $848.7K | $402.4K | $415.8K | $708.5K | $2.42M | $3.48M | $4.12M | $2.45M | $8.47M | $10.81M |
| Stockholders' Equity | $1.86M | $2.67M | $3.32M | $3.80M | $3.90M | ($1.86M) | ($406.7K) | $3.56M | $7.52M | $7.28M |
| Retained Earnings | ($246.91M) | ($246.10M) | ($245.44M) | ($244.97M) | ($243.93M) | ($237.82M) | ($236.27M) | ($231.41M) | ($227.48M) | ($224.63M) |
Cash Flow
| Line item | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $578.6K | - | - | - | ($1.12M) | - | - | - | ($3.62M) | - |
| Investing Cash Flow | - | - | - | - | - | - | - | - | $0 | - |
| Financing Cash Flow | $195.9K | - | - | - | $5.30M | - | - | - | $1.85M | - |
| CapEx | - | - | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - | - | - |
Ratios
| Metric | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 |
|---|---|---|---|---|---|---|---|---|---|---|
| Profitability | ||||||||||
| Gross margin | - | - | - | - | - | - | - | - | - | - |
| Operating margin | - | - | - | - | - | - | - | - | - | - |
| EBITDA margin | - | - | - | - | - | - | - | - | - | - |
| Net margin | - | - | - | - | - | - | - | - | - | - |
| Free cash flow margin | - | - | - | - | - | - | - | - | - | - |
| FCF / Net income | - | - | - | - | - | - | - | - | - | - |
| R&D / Revenue | - | - | - | - | - | - | - | - | - | - |
| SG&A / Revenue | - | - | - | - | - | - | - | - | - | - |
| Effective tax rate | - | - | - | - | - | - | - | - | - | - |
| Return on assets | -30.0% | - | -12.6% | -23.1% | -96.6% | - | -131.0% | -65.3% | -17.8% | - |
| Return on equity | -43.7% | - | -14.2% | -27.5% | -156.7% | - | 1196.5% | -110.2% | -37.9% | - |
| Return on invested capital | - | - | - | - | - | - | - | - | - | - |
| Liquidity | ||||||||||
| Current ratio | 3.68 | 10.25 | 10.77 | 7.60 | 6.75 | 0.51 | 1.30 | 5.62 | 5.99 | 3.31 |
| Quick ratio | 3.68 | 10.25 | 10.77 | 7.60 | 6.75 | 0.51 | 1.30 | 5.62 | 5.99 | 3.31 |
| Cash ratio | 3.54 | 6.11 | 6.68 | 4.93 | 4.90 | 0.13 | 0.55 | 2.17 | 5.09 | 2.80 |
| Leverage | ||||||||||
| Debt / Equity | - | - | - | - | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Interest coverage | - | - | - | - | - | - | - | - | -1191.6x | - |
| Equity multiplier | 1.46 | 1.15 | 1.13 | 1.19 | 1.62 | -0.87 | -9.14 | 1.69 | 2.13 | 2.49 |
| Liabilities / Assets | 0.31 | 0.13 | 0.11 | 0.16 | 0.38 | 2.15 | 1.11 | 0.41 | 0.53 | 0.60 |
| Efficiency | ||||||||||
| Asset turnover | - | - | - | - | - | - | - | - | 0.00 | - |
| Inventory turnover | - | - | - | - | - | - | - | - | - | - |
| Days sales outstanding | - | - | - | - | - | - | - | - | - | - |
| Days inventory outstanding | - | - | - | - | - | - | - | - | - | - |
| Days payable outstanding | - | - | - | - | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - | - | - | - | - |
| Valuation | ||||||||||
| P / E | - | - | - | - | - | - | - | - | - | - |
| P / B | 0.4x | - | 0.2x | 0.2x | 0.3x | - | - | 83.0x | 84.0x | - |
| P / S | - | - | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - | - | - |
| Growth | ||||||||||
| Revenue growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| Revenue CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Gross profit growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| Operating income growth (YoY) | 37.6% | - | 88.2% | 79.5% | 75.3% | - | 58.2% | 40.0% | 60.8% | - |
| Net income growth (YoY) | 86.7% | - | 90.3% | 73.4% | -114.0% | - | 53.8% | 72.1% | 78.5% | - |
| EPS growth (YoY) | 96.7% | - | 99.9% | 99.7% | 92.3% | - | -1213.9% | -823.9% | -704.6% | - |
| EPS CAGR (3y) | - | - | - | - | - | - | - | - | - | - |
| EPS CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| FCF growth (YoY) | - | - | - | - | - | - | - | - | - | - |
| FCF CAGR (5y) | - | - | - | - | - | - | - | - | - | - |
| Book value growth (YoY) | -52.3% | - | - | 6.6% | -48.2% | - | - | -86.5% | -79.8% | -85.4% |
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing Hepion Pharmaceuticals against the 5 most active filers in the same SIC group.